Related Experiment Video
Updated: Aug 14, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Medicare part D and antiretroviral therapy: issues for HIV clinicians
Laura W Cheever1, Mary R Vienna
1US Department of Health and Human Services, Health Resources and Services Administration, HIV/AIDS Bureau, Rockville, MD, USA.
Abstract:
As of January 1, 2006, Medicare Plan D will add a drug benefit to Medicare, potentially affecting antiretroviral therapy for some 60,000 to 80,000 beneficiaries with HIV infection or AIDS. Health care providers should know the basic details of Plan D and how it may affect coverage for Medicare beneficiaries with or without a previous drug benefit under Medicaid. Steps may need to be taken to ensure that there are no lapses in antiretroviral therapy during the transition from one pharmacy plan to another. This article summarizes a presentation on Medicare Plan D and antiretroviral therapy for patients with HIV or AIDS, given by Laura W. Cheever, MD, at the 8th Annual Clinical Conference for Ryan White CARE Act clinicians in New Orleans in June 2005, and developed by Dr Cheever and Mary R. Vienna, RN.
Related Concept Videos
Therapeutic Drug Monitoring: Affecting Factors
Retrovirus Life Cycles
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Pharmacokinetics in Pediatric Patients: Drug Excretion
Drug Dosing: Geriatric Patients
Pharmacokinetics: Drug–Drug Interactions

